BioPharmSignal logoBioPharmSignal

Biotech News

Verrica Pharmaceuticals Announces Acceptance of Late-Breaking Abstract Highlighting Potential Abscopal Effect of VP-315 for the Treatment of Basal Cell Carcinoma at the Upcoming 2026 Society for Investigative Dermatology Annual Meeting

Verrica Pharmaceuticals (VRCA)Verrica PharmaceuticalsCompany update

VRCA (VRCA) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is vrca.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Related news

VRCAVerrica Pharmaceuticals2026-05-05 20:05 EST

Verrica Pharmaceuticals Announces Upcoming Presentation of Phase 2 Data Highlighting the Potential Abscopal Effects of VP-315 in the Treatment of Basal Cell Carcinoma at the 2026 Society for Investigative Dermatology (SID) Annual Meeting

VRCAVerrica Pharmaceuticals2026-07-21 12:05 EST

Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel

View all latest news

Verrica Pharmaceuticals

Medical Dermatology Verrica Pharmaceuticals develops and commercializes treatments for dermatologic diseases, including viral skin conditions and non-melanoma skin cancers. YCANTH for Molluscum YCANTH is a drug-device combination containing a controlled formulation of cantharidin in a single-use applicator. It is the first FDA-approved,...

Recent company news

VRCAVerrica Pharmaceuticals2026-08-06 20:05 EST

Verrica Pharmaceuticals Reports Second Quarter 2026 Financial Results

VRCAVerrica Pharmaceuticals2026-08-06 20:01 EST

Verrica Pharmaceuticals Closes Credit Facility For Up To $27.5 Million in Non-Dilutive Growth Capital

VRCAVerrica Pharmaceuticals2026-07-30 12:05 EST

Verrica Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026

VRCAVerrica Pharmaceuticals2026-07-21 12:05 EST

Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel

VRCAVerrica Pharmaceuticals2026-06-22 12:05 EST

Verrica Pharmaceuticals Announces First U.S. Patient Dosed in the Second Pivotal Clinical Trial (COVE-3) of its Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts

Stock data

Close
5.36 USD
Market cap
99.47M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States